GlassScriptPhysician profile
Jorge J Leal
NPI 1093850927
$10,939.09
in general payments reported to CMS, 2019-2025
49 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.12 · 2020: $928 · 2021: $864 · 2022: $1,051 · 2023: $2,937 · 2024: $2,838 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,819 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,818.99 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,218.74 | 2020-2025 | Imfinzi, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $844.78 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $832.86 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $566.98 | 2020-2024 | |
| Amgen INC. | $431.09 | 2020-2024 | Nplate, Kyprolis, Vectibix |
| Regeneron Healthcare Solutions, INC. | $422.94 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $373.92 | 2023-2025 | Opdivo, Augtyro |
| Bayer Healthcare Pharmaceuticals INC. | $368.72 | 2020-2025 | |
| Incyte Corporation | $367.71 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $351.14 | 2021-2025 | Venclexta, Tecentriq |
| Astellas Pharma US INC | $349.46 | 2023-2025 | Xtandi |
| Mirati Therapeutics, INC. | $322.66 | 2023-2024 | Krazati |
| Eisai INC. | $319.33 | 2021-2024 | |
| Emd Serono, INC. | $309.74 | 2020-2023 | Bavencio |
| Genmab U.S., INC. | $306.12 | 2024-2025 | Epkinly |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $266.34 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $248.72 | 2021-2022 | |
| Daiichi Sankyo INC. | $245.98 | 2020-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $218.12 | 2023-2025 | |
| G1 Therapeutics, INC. | $193.83 | 2021-2023 | Cosela |
| Pfizer INC. | $170.30 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $149.86 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $148.74 | 2024 | Monoferric |
| Medtronic USA, INC. | $148.27 | 2020 | |
| Syndax Pharmaceuticals, INC. | $142.33 | 2025 | |
| Sobi, INC | $126.53 | 2023-2025 | |
| Gilead Sciences, INC. | $124.46 | 2024 | Trodelvy |
| Recordati_rare_diseases_inc. | $124.46 | 2024 | Sylvant |
| Kite Pharma, INC. | $124.46 | 2023 | Yescarta |
| Seagen INC. | $123.83 | 2023 | Adcetris |
| Servier Pharmaceuticals LLC | $123.07 | 2023-2025 | |
| Advanced Accelerator Applications | $114.27 | 2020 | |
| Karyopharm Therapeutics INC. | $112.81 | 2020 | |
| Lilly USA, LLC | $110.73 | 2022 | |
| Adc Therapeutics America, INC. | $82.40 | 2022 | |
| Deciphera Pharmaceuticals INC. | $77.16 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Alexion Pharmaceuticals, INC. | $67.36 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $57.28 | 2023-2024 | Vonvendi, Ninlaro |
| Puma Biotechnology, INC. | $50.50 | 2024-2025 | |
| Stemline Therapeutics INC. | $33.19 | 2023-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $26.28 | 2025 | |
| Sumitomo Pharma America, INC. | $23.20 | 2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $21.61 | 2020 | |
| Caris Mpi, INC. | $16.43 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $16.38 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $16.38 | 2025 | Rubraca |
| Aveo Pharmaceuticals, INC. | $16.05 | 2025 | |
| Amneal Pharmaceuticals LLC | $16.04 | 2025 | Alymsys |
| Novocure INC. | $15.53 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Leal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.